ArticleCureus2026
Unilateral Purtscher-Like Retinopathy Following Gemcitabine and Bevacizumab Therapy for Recurrent Cervical Carcinoma: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purtscher-like retinopathy (PLR) is a rare, vision-threatening occlusive microvasculopathy. We report a rare case of unilateral PLR following the initiation of chemotherapy for recurrent cervical carcinoma. A 54-year-old female with recurrent carcinoma of the cervical vault presented with sudden, painless diminution of vision in the left eye (visual acuity: 2/60), five days post-initiation of chemotherapy with gemcitabine and bevacizumab. Fundus examination revealed multiple superficial hemorrhages, cotton wool spots, and Purtscher flecken with macular edema, initially diagnosed elsewhere as a combined central retinal artery and vein occlusion. Systemic laboratory workup was unremarkable. A diagnosis of chemotherapy-induced PLR secondary to localized thrombotic microangiopathy was established. The patient was managed conservatively with close oncological follow-up. Gemcitabine and bevacizumab can precipitate localized thrombotic microangiopathy leading to PLR. Precise funduscopic evaluation is essential to distinguish PLR from combined retinal vascular occlusions to prevent unnecessary interventions and guide appropriate multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.